Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2016—Luminex is collaborating with the Laboratory of Molecular Evolution and Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil, to validate a multianalyte Zika virus assay developed by Luminex partner GenArraytion.
May 2016—Gold Standard Diagnostics announced FDA 510(k) clearance of its AIX1000 Rapid Plasma Reagin Automated Test System for syphilis testing.
May 2016—Streck and Sysmex Inostics, a subsidiary of Sysmex Corp., have announced that Sysmex has signed a worldwide supply and distribution agreement with Streck.
May 2016—Enzo Life Sciences now offers the Cytag TotalCGH Labeling Kit for CGH+SNP arrays. Array-based comparative genomic hybridization is a well-established method for investigating copy number variations and is used to detect a variety of genomic gains and losses from duplications and deletions, unbalanced translocations, and aneuploidies.
May 2016—The Spooner Girls Foundation, which funds research toward treatments and a cure for mitochondrial complex I deficiency, along with the University of California Irvine School of Medicine and Population Diagnostics, announced a collaborative research initiative focused on the NUBPL gene.
May 2016—Rheonix has completed development and testing of a microfluidic system and assay to simultaneously detect host anti-HIV antibodies and viral RNA in a single specimen of saliva or blood.
May 2016—Accumen, a San Diego-based health care services company, has announced the acquisition of Ann Arbor, Mich.-based Chi Solutions, a clinical laboratory consulting and management firm.
May 2016—The ALK-RET-ROS1 targeted formalin-fixed, paraffin-embedded RNA Fusion Reference Standards from Horizon are a highly characterized, biologically relevant quality control material to assess the performance of next-generation sequencing, RT-PCR, and RT-qPCR assays aimed at detecting gene fusions.
May 2016—Roche announced the launch of the Discovery Yellow Kit, an alkaline phosphatase-based detection chemistry for tissue diagnostics that produces a unique, transparent yellow signal that is not washed away during alcohol dehydration.
May 2016—Qiagen will collaborate with 10x Genomics to develop and promote comprehensive solutions for next-generation sequencing, single-cell biology, and bioinformatics.
